Check out our most popular compounded medications! Get Started
Dashboard
Formulas

Sirolimus 2 mg/mL Oral Suspension

FDA-approved generic
Dose form
Suspension
Active ingredients
Sirolimus
For prescribers
Prescription details
RxThis formula
Dose formSee below
Quantity____
SigAs directed by prescriber
Refills____
PharmacyBayview Pharmacy, Warwick RI, NCPDP 4106882
Copy prescription detailsOrder form
Controlled substance: e-prescribe (EPCS) from your EHR. Faxed and phoned prescriptions cannot be accepted for this preparation.
Send it from your EHR, or fax to (401) 284-4506. How to e-prescribe this formula
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
To prescribe, you must be a verified prescriber.
To prescribe, you must be in a state where we hold an active out-of-state pharmacy license.
Starting at
Fill my prescription
Fill my prescription
Requires a prescription from your own provider. Bayview is a pharmacy and does not prescribe.
Ships within 1 to 2 business days after pharmacist verification
HSA and FSA eligible
Check if we ship to your state
No prescription yet?

Get a sheet with everything your doctor needs to prescribe this and send it to Bayview.

Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.

For prescribersSign in for prescription details and order forms.
Compounded preparations are prepared by Bayview pursuant to a prescription for an individual patient. They are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.
Sirolimus
Suspension
66fd7b0bdc31c32733aec9f2
Service area

Can we ship this formula to your state?

Bayview fills prescriptions for patients in Connecticut, Florida, Maine, Massachusetts, New Hampshire, New Jersey, Pennsylvania and Rhode Island. New York patients are served on a limited basis while nonresident pharmacy registration is pending.

Check your state

Available in

Tap a state to check it.

Our current service area

Currently licensed Limited basis, registration pending Not available for this formula Not currently licensed

Select a state on the map or use the checker.

Prepared to a prescriber's order for one patient. Not FDA-approved.

This formulation

This is a compounded suspension containing sirolimus, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.

FDA product listings

These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.

FDA-approved products containing sirolimus are listed in tablet, solution, gel and injection forms.

Storage category and dating

Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.

Sources

Why prescribers order this

Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.

Sirolimus is an mTOR inhibitor immunosuppressant that compounding pharmacies most often prepare as topical creams, ointments and gels for skin conditions.

About this ingredient

Sirolimus, also called rapamycin, binds a protein inside cells called FKBP-12, and the pair blocks mTOR, a key enzyme that controls cell growth and immune cell activation. Manufactured sirolimus tablets and oral solution are FDA-approved to prevent organ rejection in kidney transplant recipients and to treat lymphangioleiomyomatosis (LAM), a rare lung disease. Hyftor (sirolimus topical gel, Nobelpharma) is approved for facial angiofibroma associated with tuberous sclerosis, and Fyarro, an albumin-bound injectable form, is approved for advanced malignant PEComa, a rare tumor. Dermatologists have used topical sirolimus off-label for other skin conditions, so a prescriber may order it compounded in a cream or ointment base, a different strength, or for an area the gel is not labeled for. Compounded preparations are not FDA-approved and require a prescription.

Safety and interactions

Oral sirolimus carries a boxed warning for immunosuppression, which raises the risk of serious infections, lymphoma and other cancers, and states it is not recommended in liver or lung transplant patients because of deaths, graft loss and airway healing problems. Other warnings include high cholesterol and triglycerides, slow wound healing, swelling, lung inflammation and kidney effects. Do not use it if you are allergic to sirolimus. Avoid grapefruit juice, and tell your prescriber about antifungals, certain antibiotics, rifampin and ACE inhibitors. Avoid live vaccines. Sirolimus can cause fetal harm; the oral labels recommend reliable birth control during treatment and for 12 weeks after. The Hyftor gel label notes it is absorbed through skin and does not recommend breastfeeding during treatment. LactMed says topical sirolimus is unlikely to affect a nursing infant if it is kept off the nipple area and the baby's skin does not touch treated skin; oral sirolimus should be used with caution while breastfeeding, especially with a newborn or preterm infant. Talk to your prescriber or pharmacist about irritation or signs of infection.

Sirolimus binds FKBP-12, and the complex inhibits mTOR. Per the oral label, systemic availability after oral solution is about 14%, plasma protein binding about 92% (mainly albumin), and mean terminal half-life about 62 hours in stable renal transplant patients. It is a substrate of CYP3A4 and P-gp; strong inhibitors such as voriconazole, itraconazole and clarithromycin are not recommended, and rifampin is a strong inducer. Labeled indications: oral tablets and solution for renal transplant prophylaxis and LAM; Hyftor gel for facial angiofibroma in tuberous sclerosis. After Hyftor application, sirolimus blood concentrations ranged from undetectable to very low with no evidence of accumulation. Prescribers have ordered compounded topical sirolimus for facial angiofibromas, port-wine stains (with pulsed-dye laser) and cutaneous vascular anomalies; a systematic review in Clinical and Experimental Dermatology describes this off-licence use and found localized irritation and pruritus the most common adverse effects. Dosing is per prescriber. For oral therapy, trough level monitoring is recommended for all patients, along with lipids, renal function and proteinuria. Sirolimus is not a controlled substance.

Sources

Using and storing

How it is used

Shake the bottle well before every dose so the medication is evenly mixed. Measure with the oral syringe or dosing cup provided, using the milliliter markings, and never a kitchen spoon. Take it by mouth as your label directs. Rinse the syringe after use and recap the bottle.

Storing it

Water-based suspensions are aqueous preparations. Under USP <795>, a preserved suspension usually carries a beyond-use date of up to 35 days at room temperature or refrigerated; an unpreserved one is refrigerated for up to 14 days. Oil-based suspensions are nonaqueous and may carry up to 90 days. Your label states storage and the beyond-use date. Keep out of reach of children and discard after that date.

Sources

Prescribing and ordering FAQs

Formula Information

A small arrow pointing down

Drug Interactions

A small arrow pointing down

How Does it Work

A small arrow pointing down

Frequently Asked Questions

A small arrow pointing down

About this compounded preparation

This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.

A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.

Formulas and/or material listed are not to be interpreted as a promise, guarantee or claim of therapeutic efficacy or safety. The information contained herein is not intended to replace or substitute for conventional medical care, or encourage its abandonment. Every patient is unique, and formulas should be adjusted to meet their individual needs.

No compounded medications are reviewed by the FDA for safety or efficacy.
For prescribers

How to e-prescribe this formula

Controlled substance: e-prescribe only (EPCS). Faxed, phoned, and handwritten prescriptions cannot be filled. Rhode Island law (R.I. Gen. Laws § 21-28-3.18) requires Schedule II to V prescriptions to be transmitted electronically.
1

Find Bayview in your EHR's pharmacy directory

Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.

NCPDP4106882NPI1750455143Address3844 Post Rd, Warwick, RI 02886Phone(401) 284-4505Fax(401) 284-4506
2

Enter the formula as a compound

Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.

Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.

3

Copy the prescription details

RxFormula name
Dose formDose form
Quantity________
SigAs directed by prescriber
Refills____
PharmacyBayview Pharmacy, Warwick RI, NCPDP 4106882
Copy prescription details

Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.

4

Send it

Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.

Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.

Do not use Notes to Pharmacy for the formula. Some EHRs keep that field internal and never transmit it. A prescription that arrives without the formula is delayed while we call your office.

Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.

Sirolimus 2 mg/mL Oral Suspension
Suspension
30 mL
controlled

Take orally

Once daily